Gateway for Cancer Research
55
15
32
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
18.2%
10 terminated/withdrawn out of 55 trials
54.5%
-32.0% vs industry average
2%
1 trials in Phase 3/4
125%
15 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (55)
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Role: collaborator
A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Role: collaborator
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
Role: collaborator
Trial of C134 in Patients With Recurrent GBM
Role: collaborator
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Role: collaborator
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Role: collaborator
RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer
Role: collaborator
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
Role: collaborator
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Role: collaborator
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
Role: collaborator
The Effect of Acupuncture on Nerve Pain Caused by Taxane (Chemotherapy) Treatment
Role: collaborator
EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors
Role: collaborator
A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
Role: collaborator
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
Role: collaborator
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
Role: collaborator
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
Role: collaborator
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
Role: collaborator
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Role: collaborator
Personalized Autologous Transplant for Multiple Myeloma
Role: collaborator
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
Role: collaborator